Beimei Pharma and Cipla reached an exclusive license and supply agreementin China for two products that have been approved for marketing in the United States 

On October 9, 2020, Shenzhen Beimei Pharma Co., Ltd. (hereinafter referred to as "Beimei Pharma") and Cipla Ltd (hereinafter referred to as "Cipla") signed an exclusive and supply agreement in China for two products that have been approved for marketing in the United States According to the agreement, Beimei Pharma is responsible for its registration and commercialization in Mainland China.

Product One:

This product is currently the only child-specific generic proton-pump inhibitor (PPI) preparation approved by the US FDA for marketing. It will be declared for marketing as an exclusive formulation in China and will Provide new PPI options for Chinese children and patients with dysphagia.

According to data from the World Health Organization, the global digestive system incidence rate is 10%-12%, and the urban digestive system incidence rate is 11.2%, which is basically the same as many developed countries in Europe and America. The most common diseases of the digestive system are ulcer disease, superficial gastritis and chronic atrophic gastritis. At present, PPI is the most advanced class of drugs for the treatment of peptic ulcers. It can quickly cure ulcers by efficiently and quickly inhibiting gastric acid secretion and eliminating Helicobacter pylori. It is the most widely used clinically and most effective drugs for the treatment of acid-related diseases in the past ten years.

According to IQVIA data, the global PPI market in 2019 exceeded US$15 billion, and Chinese PPI market exceeded US$2.5 billion. The pharmaceutical preparation belongs to the second-generation PPI drug, which has the characteristics of fast onset, long action time and small side effects. The market has grown rapidly and has been the world's best-selling PPI for many consecutive years. The drug molecule currently has no child-specific dosage form in China. The successful listing of this product in China will well meet the needs of children and patients with swallowing difficulties.

Product two:

The drug molecule is the first oral iron repellent approved by the US FDA for routine use. As a molecular analog of the drug, this product has been approved by the US FDA for marketing. It can be used in patients over 2 years of age and is resistant to various iron overloads. There is a therapeutic effect.

Since the drug molecule was launched, its annual sales have maintained good growth. In 2019, the global sales of iron-repellent drugs were approximately US$1.5 billion. The drug has the largest sales volume and is an internationally recognized first-line drug. No domestic dosage form has been approved for marketing yet. This product will be declared for marketing as an exclusive imported imitation preparation. Compared with other dosage forms already on the market, this product has the advantages of good absorption and less side effects, which can greatly improve the compliance of children with this product.

About Cipla

Cipla, founded in 1935, is a leading global pharmaceutical company focusing on complex generic drugs. Cipla utilizes a high technology platform to produce more than 50 dosage forms and more than 1,500 products in 44 production bases around the world to meet the needs of more than 80 markets. According to IQVIA data, Cipla ranks among the top three in the Indian pharmaceutical industry and the top three in the South African pharmaceutical private market, and is one of the most commonly prescribed generic drug manufacturers in the United States.

About Beimei Pharma

Beimei Pharma is focused in the field of pediatric prescription drugs, and aims to become a new-styled pharmaceutical company integrated with R&D, in-licensing, production and sales. It takes independent R&D and the in-licensing of domestic and international pediatric products as its strategic direction. The current product pipeline covers the respiratory, anti-infection (antibacterial), neuroscience, gastroenterology and others. Beimei Pharma is committed to providing Chinese pediatric patients with convenient, accurate, excellent-taste and high-quality products.